FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387301981> ?p ?o ?g. }

• W4387301981 endingPage "S172" @default.
• W4387301981 startingPage "S172" @default.
• W4387301981 abstract "In the “COVID-19 era,” it is crucial to understand the impact of SARS-CoV-2 infection on patients with muscular dystrophy. We conducted a retrospective study using data from patients with muscular dystrophy affected by COVID-19 from January 2020 to October 2022. We obtained data from 127 patients (129 infections) from nine centers in Japan from 2020 to 2022, with 122 patients in 2022. Patients had the following forms of muscular dystrophy: dystrophinopathies (55), congenital muscular dystrophies (21), myotonic dystrophy (19), facioscapulohumeral muscular dystrophy (10), autoimmune diseases (4), other myopathies (13), and spinal muscular atrophy (5). Forty-two patients received non-invasive ventilation [NIV], and three received tracheal mechanical ventilation. Sources of transmission were as follows: family members (52), institutions/caregivers (21), work/outgoing (16), and unknown sources (38). Seventy-six patients were vaccinated, 38 were unvaccinated, and the vaccine status of 13 was unknown. Fifty-eight patients were hospitalized. Of the 45 patients admitted to the responding centers, CT showed pneumonia in 12 patients. Thirty-four patients received the following therapeutics for COVID-19: remdesivir (17), sotrovimab (13), molnupiravir (5), nirmatrelvir (4), steroids (4), and favipiravir (2). Although most patients recovered, 17 needed oxygen administration; among them, six patients also required changes in mechanical ventilation. Two patients died. A patient with Becker muscular dystrophy and advanced heart failure died from cardiogenic shock after COVID-19 infection. A patient with congenital myotonic dystrophy and dysphagia died from difficulty in clearing sputum. Muscular dystrophy did not exacerbate COVID-19. However, COVID-19 may aggravate respiratory status and heart failure. Patients with muscular dystrophy should continue to take appropriate infection control measures and seek medical attention and appropriate treatment if they have COVID-19. In the “COVID-19 era,” it is crucial to understand the impact of SARS-CoV-2 infection on patients with muscular dystrophy. We conducted a retrospective study using data from patients with muscular dystrophy affected by COVID-19 from January 2020 to October 2022. We obtained data from 127 patients (129 infections) from nine centers in Japan from 2020 to 2022, with 122 patients in 2022. Patients had the following forms of muscular dystrophy: dystrophinopathies (55), congenital muscular dystrophies (21), myotonic dystrophy (19), facioscapulohumeral muscular dystrophy (10), autoimmune diseases (4), other myopathies (13), and spinal muscular atrophy (5). Forty-two patients received non-invasive ventilation [NIV], and three received tracheal mechanical ventilation. Sources of transmission were as follows: family members (52), institutions/caregivers (21), work/outgoing (16), and unknown sources (38). Seventy-six patients were vaccinated, 38 were unvaccinated, and the vaccine status of 13 was unknown. Fifty-eight patients were hospitalized. Of the 45 patients admitted to the responding centers, CT showed pneumonia in 12 patients. Thirty-four patients received the following therapeutics for COVID-19: remdesivir (17), sotrovimab (13), molnupiravir (5), nirmatrelvir (4), steroids (4), and favipiravir (2). Although most patients recovered, 17 needed oxygen administration; among them, six patients also required changes in mechanical ventilation. Two patients died. A patient with Becker muscular dystrophy and advanced heart failure died from cardiogenic shock after COVID-19 infection. A patient with congenital myotonic dystrophy and dysphagia died from difficulty in clearing sputum. Muscular dystrophy did not exacerbate COVID-19. However, COVID-19 may aggravate respiratory status and heart failure. Patients with muscular dystrophy should continue to take appropriate infection control measures and seek medical attention and appropriate treatment if they have COVID-19." @default.
• W4387301981 created "2023-10-04" @default.
• W4387301981 creator A5000588161 @default.
• W4387301981 creator A5011012573 @default.
• W4387301981 creator A5020634547 @default.
• W4387301981 creator A5036975652 @default.
• W4387301981 creator A5045970417 @default.
• W4387301981 creator A5056741629 @default.
• W4387301981 creator A5076534477 @default.
• W4387301981 creator A5086694128 @default.
• W4387301981 creator A5087966860 @default.
• W4387301981 creator A5091878292 @default.
• W4387301981 creator A5092993055 @default.
• W4387301981 date "2023-10-01" @default.
• W4387301981 modified "2023-10-04" @default.
• W4387301981 title "P110 A multicenter retrospective study of the impact of COVID-19 on patients with muscular dystrophies" @default.
• W4387301981 doi "https://doi.org/10.1016/j.nmd.2023.07.417" @default.
• W4387301981 hasPublicationYear "2023" @default.
• W4387301981 type Work @default.
• W4387301981 citedByCount "0" @default.
• W4387301981 crossrefType "journal-article" @default.
• W4387301981 hasAuthorship W4387301981A5000588161 @default.
• W4387301981 hasAuthorship W4387301981A5011012573 @default.
• W4387301981 hasAuthorship W4387301981A5020634547 @default.
• W4387301981 hasAuthorship W4387301981A5036975652 @default.
• W4387301981 hasAuthorship W4387301981A5045970417 @default.
• W4387301981 hasAuthorship W4387301981A5056741629 @default.
• W4387301981 hasAuthorship W4387301981A5076534477 @default.
• W4387301981 hasAuthorship W4387301981A5086694128 @default.
• W4387301981 hasAuthorship W4387301981A5087966860 @default.
• W4387301981 hasAuthorship W4387301981A5091878292 @default.
• W4387301981 hasAuthorship W4387301981A5092993055 @default.
• W4387301981 hasBestOaLocation W43873019811 @default.
• W4387301981 hasConcept C126322002 @default.
• W4387301981 hasConcept C167135981 @default.
• W4387301981 hasConcept C187212893 @default.
• W4387301981 hasConcept C2777080012 @default.
• W4387301981 hasConcept C2777914695 @default.
• W4387301981 hasConcept C2778063965 @default.
• W4387301981 hasConcept C2778558090 @default.
• W4387301981 hasConcept C2779030066 @default.
• W4387301981 hasConcept C2779134260 @default.
• W4387301981 hasConcept C71924100 @default.
• W4387301981 hasConceptScore W4387301981C126322002 @default.
• W4387301981 hasConceptScore W4387301981C167135981 @default.
• W4387301981 hasConceptScore W4387301981C187212893 @default.
• W4387301981 hasConceptScore W4387301981C2777080012 @default.
• W4387301981 hasConceptScore W4387301981C2777914695 @default.
• W4387301981 hasConceptScore W4387301981C2778063965 @default.
• W4387301981 hasConceptScore W4387301981C2778558090 @default.
• W4387301981 hasConceptScore W4387301981C2779030066 @default.
• W4387301981 hasConceptScore W4387301981C2779134260 @default.
• W4387301981 hasConceptScore W4387301981C71924100 @default.
• W4387301981 hasLocation W43873019811 @default.
• W4387301981 hasOpenAccess W4387301981 @default.
• W4387301981 hasPrimaryLocation W43873019811 @default.
• W4387301981 hasRelatedWork W1152728845 @default.
• W4387301981 hasRelatedWork W1557757630 @default.
• W4387301981 hasRelatedWork W1967818989 @default.
• W4387301981 hasRelatedWork W2043470219 @default.
• W4387301981 hasRelatedWork W2083077431 @default.
• W4387301981 hasRelatedWork W2101318255 @default.
• W4387301981 hasRelatedWork W2116927707 @default.
• W4387301981 hasRelatedWork W2158739907 @default.
• W4387301981 hasRelatedWork W2344301892 @default.
• W4387301981 hasRelatedWork W27944532 @default.
• W4387301981 hasVolume "33" @default.
• W4387301981 isParatext "false" @default.
• W4387301981 isRetracted "false" @default.
• W4387301981 workType "article" @default.